Literature DB >> 24308543

Ex vivo expansion of hematopoietic stem- and progenitor cells from cord blood in coculture with mesenchymal stroma cells from amnion, chorion, Wharton's jelly, amniotic fluid, cord blood, and bone marrow.

Caroline Klein1, Julian Strobel, Jürgen Zingsem, Richard H Richter, Tamme W Goecke, Matthias W Beckmann, Reinhold Eckstein, Volker Weisbach.   

Abstract

In most cases, the amount of hematopoietic stem and progenitor cells (HSPCs) in a single cord blood (CB) unit is not sufficient for allogenic transplantation of adults. Therefore, two CB units are usually required. The ex vivo expansion of HSPCs from CB in coculture with mesenchymal stroma cells (MSCs) might be an alternative. It was investigated, whether bone marrow-derived MSCs, which have to be obtained in an invasive procedure, introduce a further donor and increases the risk of transmissible infectious diseases for the patient can be replaced by MSCs from amnion, chorion, Wharton's jelly, amniotic fluid, and CB, which can be isolated from placental tissue which is readily available when CB is sampled. In a two-step ex vivo coculture mononuclear cells from cryopreserved CB were cultured with different MSC-feederlayers in a medium supplemented with cytokines (stem cell factor, thrombopoietin [TPO], and granulocyte colony-stimulating factor). Expansion rates were analyzed as well, by long-term culture-initiating cell (LTC-IC) and colony-forming unit (CFU) assays, as by measuring CD34(+)- and CD45(+)-cells. Due to the comparably low number of 5×10(2) to 1×10(4) CD34(+)-cells per cm(2) MSC-monolayer, we observed comparably high expansion rates from 80 to 391,000 for CFU, 70 to 313,000 for CD34(+)-, and 200 to 352,000 for CD45(+)-cells. Expansion of LTC-IC was partly observed. Compared to the literature, we found a better expansion rate of CD34(+)-cells with MSCs from all different sources. This is probably due to the comparably low number of 5×10(2) to 1×10 CD34(+)-cells per cm(2) MSC-monolayer we used. Comparably, high expansion rates were observed from 80 to 391,000 for CFUs, 70 to 313,000 for CD34(+)-, and 200 to 352,000 for CD45(+)-cells. However, the expansion of CD34(+)-cells was significantly more effective with MSCs from bone marrow compared to MSCs from amnion, chorion, and Wharton's jelly. The comparison of MSCs from bone marrow with MSCs from CB and amniotic fluid showed no significant difference. We conclude that MSCs from placental tissues might be useful in the expansion of HSPCs, at least if low numbers of CD34(+)-cells per cm(2) MSC-monolayer and a high TPO concentration are implemented in the expansion culture.

Entities:  

Mesh:

Year:  2013        PMID: 24308543     DOI: 10.1089/ten.tea.2013.0073

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  14 in total

1.  Comparable osteogenic capacity of mesenchymal stem or stromal cells derived from human amnion membrane and bone marrow.

Authors:  Mehran Ghasemzadeh; Ehteramolsadat Hosseini; Mohammadhossein Ahmadi; Maedeh Kamalizad; Naser Amirizadeh
Journal:  Cytotechnology       Date:  2018-01-05       Impact factor: 2.058

Review 2.  Optimizing autologous cell grafts to improve stem cell gene therapy.

Authors:  Nikoletta Psatha; Garyfalia Karponi; Evangelia Yannaki
Journal:  Exp Hematol       Date:  2016-04-19       Impact factor: 3.084

3.  Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Authors:  Dandan Li; Grace Chiu; Brea Lipe; Richard A Hopkins; Jacquelyn Lillis; John M Ashton; Soumen Paul; Omar S Aljitawi
Journal:  Blood Adv       Date:  2019-04-09

Review 4.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

5.  Comparison of serum granulocyte colony-stimulating factor levels between preterm and term births.

Authors:  Çiğdem Kılıç; Mustafa Uğur; Bekir Serdar Ünlü; Yunus Yıldız; İshak Artar; Pervin Karlı; Kadriye Turgut
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-12-01

6.  Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells.

Authors:  Francisca Alcayaga-Miranda; Jimena Cuenca; Patricia Luz-Crawford; Carolina Aguila-Díaz; Ainoa Fernandez; Fernando E Figueroa; Maroun Khoury
Journal:  Stem Cell Res Ther       Date:  2015-03-17       Impact factor: 6.832

7.  Differential ability of MSCs isolated from placenta and cord as feeders for supporting ex vivo expansion of umbilical cord blood derived CD34(+) cells.

Authors:  Darshana Kadekar; Vaijayanti Kale; Lalita Limaye
Journal:  Stem Cell Res Ther       Date:  2015-10-19       Impact factor: 6.832

8.  IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway.

Authors:  Xinyuan Yang; Jingchun Du; Xia Xu; Chun Xu; Wu Song
Journal:  J Immunol Res       Date:  2014-05-26       Impact factor: 4.818

9.  Development of a Xeno-Free Feeder-Layer System from Human Umbilical Cord Mesenchymal Stem Cells for Prolonged Expansion of Human Induced Pluripotent Stem Cells in Culture.

Authors:  Qing Zou; Mingjun Wu; Liwu Zhong; Zhaoxin Fan; Bo Zhang; Qiang Chen; Feng Ma
Journal:  PLoS One       Date:  2016-02-16       Impact factor: 3.240

Review 10.  The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate.

Authors:  Hamze Timari; Karim Shamsasenjan; Aliakbar Movassaghpour; Parvin Akbarzadehlaleh; Davod Pashoutan Sarvar; Sara Aqmasheh
Journal:  Adv Pharm Bull       Date:  2017-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.